Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer

• DOI: 10.1007/s10549-022-06531-5
• Publication Date: 2022-02-06T15:02:42Z
• Authors: Yousif Kariri; Michael S. Toss; Mansour Alsaleem; Khloud A. Elsharawy; Chitra Joseph; Nigel P. Mongan; Andrew R. Green; Emad A. Rakha
• Keywords: Nottingham Breast Cancer Research Centre; lymphovascular invasion; Breast Neoplasms; Prognosis; Immunohistochemistry; 3. Good health; 03 medical and health sciences; breast cancer; Preclinical Study; 0302 clinical medicine; Ubiquitin-Conjugating Enzymes; outcome; Biomarkers, Tumor; Humans; Female; progression; prognosis; RNA, Messenger; UBE2C

The Ubiquitin-conjugating enzyme 2C (UBE2C) is essential for the ubiquitin-proteasome system and involved in cancer cell migration apoptosis. This study aimed to determine prognostic value of UBE2C invasive breast (BC).UBE2C was evaluated using Molecular Taxonomy Breast Cancer International Consortium (n = 1980), Genome Atlas 854) Kaplan-Meier Plotter 3951) cohorts. protein expression assessed immunohistochemistry BC cohort 619). correlation between UBE2C, clinicopathological parameters patient outcome assessed.High mRNA expressions were correlated with features poor prognosis, including high tumour grade, large size, presence lymphovascular invasion, hormone receptor negativity HER2 positivity. High showed a negative association E-cadherin, positive adhesion molecule N-cadherin, matrix metalloproteinases cyclin-related genes. There cycle-associated biomarkers, p53, Ki67, EGFR PI3K. an independent predictor (p 0.011, HR 1.45, 95% CI; 1.10-1.93).This indicates that biomarker BC. These results warrant further functional validation as potential therapeutic target